Sjögren’s syndrome is a chronic autoimmune disease in which the immune system attacks the body’s moisture-producing glands, most commonly the salivary and tear glands. The hallmark symptoms are persistent dry mouth and dry eyes, but the disease can reach well beyond those glands, affecting the joints, lungs, kidneys, nerves, and skin in roughly a third to four out of ten patients.1PubMed. Pulmonary and Bronchiolar Involvement in Sjogren’s Syndrome It overwhelmingly affects women, with most diagnoses occurring around or after menopause, and its underlying causes involve an unusual collision of genetics, immune signaling gone haywire, and hormonal shifts that researchers are still working to untangle.
What Goes Wrong in the Immune System
In a healthy person, immune cells leave the salivary and tear glands alone. In Sjögren’s syndrome, clusters of white blood cells (mostly a type called CD4+ T-cells) infiltrate those glands and accumulate around the ducts, progressively damaging the tissue that produces saliva and tears.2PubMed Central. Current Aspects of Pathogenesis in Sjögren’s Syndrome Over time, the infiltrate can expand and replace functioning glandular tissue entirely, which is why dryness tends to worsen as the disease progresses.
The immune attack also involves B-cells, which produce autoantibodies, the most characteristic being anti-Ro/SSA and anti-La/SSB. These antibodies target proteins inside cells and are found in the blood of most people with the primary form of the disease. Anti-Ro/SSA antibodies are the single most useful blood marker for diagnosis, while anti-La/SSB appears to be more specific to Sjögren’s syndrome itself.3Journal of Translational Autoimmunity. Autoantibodies in Sjögren’s syndrome and its classification criteria Their presence is linked to earlier disease onset, more salivary gland destruction, and a higher likelihood of symptoms outside the glands.4PubMed. Anti-Ro (SSA)/La (SSB) antibodies and Sjögren’s syndrome Interestingly, there is no conclusive evidence that these autoantibodies themselves directly destroy glandular tissue. They are powerful disease markers, but the tissue damage appears to come primarily from the infiltrating T-cells, which produce molecules capable of punching holes in gland cells.5PubMed. Sjögren’s syndrome: immunobiology of exocrine gland dysfunction
Not every patient fits this picture neatly. Some people with classic dry-mouth and dry-eye symptoms show no focal lymphocytic infiltration in their salivary gland biopsies at all, pointing to other mechanisms of gland dysfunction, possibly autoantibodies that block receptors controlling saliva release or altered expression of water-channel molecules in gland cells.6PubMed Central. Sjögren’s Syndrome without focal lymphocytic infiltration of the salivary glands This heterogeneity is one reason the disease can be difficult to pin down.
Causes and Risk Factors
No single cause has been identified. The current understanding is that Sjögren’s syndrome arises from a combination of genetic susceptibility, immune-system abnormalities, hormonal influences, and likely environmental triggers.
On the genetic side, certain variants of immune-related genes increase the odds. People who carry specific HLA-DR and HLA-DQ alleles have a higher baseline risk.5PubMed. Sjögren’s syndrome: immunobiology of exocrine gland dysfunction Beyond HLA, variants in genes involved in interferon signaling and inflammation have been linked to the disease. For example, a particular variant of the STAT4 gene has been found to increase risk more than eightfold, and a variant in the TNFAIP3 gene raises risk roughly sixfold.7Modern Rheumatology Journal. Association of IRF5 (rs2004640), STAT4 (rs7574865), and TNFAIP3 (rs6920220, rs2230926) gene polymorphisms with primary Sjögren’s syndrome and its complication, MALT-lymphoma These numbers sound dramatic, but they describe risk in people who carry specific genotypes compared to those who do not, not the absolute likelihood of developing the disease.
A recurring theme in Sjögren’s research is what scientists call the “interferon signature,” an overactivation of genes regulated by type I interferons. Multiple studies have found this signature in both the blood and the salivary glands of patients.8PubMed Central. Interferons in Sjögren’s Syndrome: Genes, Mechanisms, and Effects Interferons are proteins the body normally uses to fight viruses, but in Sjögren’s they appear to stay switched on inappropriately, fueling lymphocyte infiltration into the glands, autoantibody production, and gland cell death. The trigger for this chronic activation remains unclear, though viral infections and immune-complex formation are leading suspects.9PubMed. Type I interferons in Sjögren’s syndrome
Hormones play a major role in who gets the disease and when. Estrogen and androgens help protect the exocrine glands, and their decline around menopause coincides with peak onset of Sjögren’s, typically between ages 55 and 60. Even after menopause, lower but persistent estrogen levels appear to continue driving autoantibody diversity, which may partly explain why the disease keeps progressing.10PubMed Central. Sex differences in Sjögren’s syndrome: a comprehensive review of immune mechanisms
Symptoms Beyond Dry Eyes and Dry Mouth
The dryness itself can be debilitating. Reduced saliva leads to difficulty swallowing and speaking, accelerated tooth decay, and frequent oral infections. Reduced tear production causes a gritty, burning sensation, light sensitivity, and damage to the corneal surface. But Sjögren’s is far from limited to the eyes and mouth. Patients often experience drying of other mucosal surfaces, along with systemic symptoms, particularly fatigue and joint pain.11Rheumatology. How to treat Sjögren’s syndrome
Fatigue deserves special mention because it is often the most disabling symptom. Many patients describe it as a profound, unrelenting exhaustion unrelated to how much they sleep. It does not always track with the severity of dryness or lab markers, making it tricky to manage. A supervised walking program studied over 16 weeks improved aerobic capacity, exercise tolerance, and patient-reported fatigue without making the disease worse, suggesting that gentle, regular physical activity is worth pursuing even though it does not address the underlying autoimmunity.12PubMed Central. Managing fatigue in patients with primary Sjögren’s syndrome: challenges and solutions
Systemic involvement occurs in roughly 30 to 40 percent of cases and can affect the lungs, kidneys, skin, and nervous system.1PubMed. Pulmonary and Bronchiolar Involvement in Sjogren’s Syndrome Cutaneous vasculitis, which presents as purplish spots or skin ulcers on the lower legs, is associated with more aggressive disease. Patients with skin vasculitis are far more likely to also have peripheral neuropathy, Raynaud’s phenomenon (fingers turning white or blue in the cold), joint inflammation, and kidney involvement than those without it.13Medicine. Cutaneous Vasculitis in Primary Sjögren Syndrome: Classification and Clinical Significance of 52 Patients
Primary Versus Secondary Forms
Sjögren’s syndrome is divided into primary and secondary forms. Primary Sjögren’s occurs on its own. Secondary Sjögren’s develops alongside another autoimmune condition, most commonly rheumatoid arthritis or lupus.14PubMed Central. Classification criteria for secondary Sjögren’s syndrome. Current state of knowledge. The distinction matters clinically because the two forms can look somewhat different.
People with primary Sjögren’s tend to have more prominent oral symptoms, are more likely to develop swollen parotid (cheek-area) glands, and carry anti-Ro/La antibodies at higher rates and higher levels. In one large comparison, parotid enlargement appeared in about 56 percent of primary cases but only 9 percent of secondary cases. Raynaud’s phenomenon, by contrast, was more common in secondary Sjögren’s.15The Journal of Rheumatology. Similarities and Differences Between Primary and Secondary Sjögren’s Syndrome The degree of glandular inflammation, measured by biopsy, was similar between the two forms, though the primary form showed a higher ratio of B-cells in the infiltrate.
How Sjögren’s Syndrome Is Diagnosed
Diagnosis can be frustratingly slow, often taking years from symptom onset. No single test confirms the disease, so clinicians rely on a combination of blood work, functional tests, and sometimes a minor salivary gland biopsy. Anti-Ro/SSA antibodies in the blood are the strongest serological indicator, but they are not specific to Sjögren’s alone and can appear in lupus and other conditions.3Journal of Translational Autoimmunity. Autoantibodies in Sjögren’s syndrome and its classification criteria
The lip biopsy, in which a small sample of minor salivary glands is taken from the inside of the lower lip, looks for clusters of immune cells. Recent research has shown that evaluating multiple features on biopsy rather than just one raises the specificity of the test from about 84 percent to 95 percent.16PubMed. Increased Diagnostic Accuracy of the Labial Gland Biopsy in Primary Sjögren Syndrome When Multiple Histopathological Features Are Included That is a meaningful improvement, since a false positive on a biopsy could lead to unnecessary treatment.
Salivary gland ultrasound is gaining traction as a non-invasive alternative. When added to existing diagnostic criteria that include blood tests, saliva flow measurements, and biopsy results, ultrasound boosted sensitivity from about 78 percent to 87 percent without sacrificing specificity.17PubMed. Contribution of salivary gland ultrasonography to the diagnosis of Sjögren’s syndrome: toward new diagnostic criteria? This is relevant because not every patient wants or is able to undergo a lip biopsy, and ultrasound can help tip the scales when blood tests and symptoms are suggestive but not definitive.
Treating Dryness
The mainstays for dry mouth and dry eyes are still symptom-management tools: artificial tears, saliva substitutes, and good dental hygiene. But prescription medications that stimulate whatever functional gland tissue remains can make a significant difference.
Pilocarpine, taken orally, boosts both salivary and tear secretion. In a randomized trial comparing pilocarpine drops to artificial saliva over 12 weeks, pilocarpine was more effective at increasing secretion, though sweating, nausea, and increased salivation (to the point of drooling) were common side effects.18PubMed Central. Effectiveness of pharmacological interventions for Sjogren syndrome – A systematic review Cevimeline, a related drug with a similar mechanism, also significantly increases salivary flow and appears to have a favorable safety profile at standard doses, particularly for patients whose gland destruction is mild to moderate.19Current Therapeutic Research. Efficacy of Cevimeline on Xerostomia in Sjögren’s Syndrome Patients: A Systematic Review and Meta-Analysis of Randomized Clinical Trials If the glands are too damaged, these drugs have less tissue to stimulate and become less effective.
For the eyes, autologous serum eye drops, made from a patient’s own blood, have shown sustained improvement in corneal surface damage and tear stability over long-term use. Adding punctal plugs, tiny devices inserted into the tear ducts to prevent tears from draining away, provided an additional benefit on top of the serum drops.20Cornea. Effectiveness of Autologous Serum Eye Drops Combined With Punctal Plugs for the Treatment of Sjögren Syndrome–Related Dry Eye This combination can be particularly useful for patients who get insufficient relief from standard artificial tears or cyclosporine eye drops.
Systemic Therapies and Their Limitations
When Sjögren’s syndrome causes significant organ involvement, such as joint inflammation, skin vasculitis, or nerve damage, systemic drugs come into the picture. Hydroxychloroquine is probably the most widely prescribed systemic therapy for Sjögren’s, but the evidence behind it is surprisingly thin. In the largest randomized trial specifically testing it, hydroxychloroquine did not beat placebo on the primary outcome measure over 24 weeks, either for overall symptoms or for disease activity in patients with systemic involvement.21JAMA. Effects of Hydroxychloroquine on Symptomatic Improvement in Primary Sjögren Syndrome: The JOQUER Randomized Clinical Trial Despite this, many rheumatologists continue to prescribe it, partly out of clinical experience with individual patients and partly because few alternatives have performed better in trials.
One more promising finding comes from combining leflunomide with hydroxychloroquine. A phase 2 trial found that this combination improved disease activity scores compared to placebo, suggesting the two drugs together may do what hydroxychloroquine alone could not.22The Lancet Rheumatology. Efficacy and safety of leflunomide–hydroxychloroquine combination therapy in primary Sjögren’s syndrome (REBATe): a placebo-controlled, double-blinded, randomised phase 2A clinical trial However, this needs to be validated in larger studies before it becomes a standard recommendation.
Rituximab, a biologic drug that depletes B-cells and has been transformative in other autoimmune diseases, has been a disappointment in Sjögren’s. A systematic review and meta-analysis of B-cell-targeted therapies concluded that rituximab was not effective in the primary Sjögren’s trials conducted to date, based on the study designs and outcome measures used.23PubMed. Efficacy and safety of biological DMARDs modulating B cells in primary Sjögren’s syndrome: Systematic review and meta-analysis This does not mean B-cell depletion is irrelevant, just that the trials have not yet shown the approach works well enough at a population level. Some individual patients with severe disease appear to benefit, which is part of why research continues.
Emerging Therapies
The drug pipeline for Sjögren’s syndrome has expanded considerably. A recent systematic review identified 32 novel agents in clinical trials, including ten in the advanced phase 3 stage. One of the more notable is nipocalimab, an antibody that lowers circulating immunoglobulin levels. In preliminary results among patients with certain autoantibody profiles, it showed meaningful improvement in disease activity at the higher dose tested.24Best Practice & Research Clinical Rheumatology. Novel therapies in Sjögren’s disease: A systematic review of the literature
Further out on the experimental horizon, CAR-T cell therapy, in which a patient’s own T-cells are engineered to target and deplete B-cells, is being explored for autoimmune diseases including Sjögren’s. Case reports of proteasome inhibitors, originally developed for blood cancers, have shown striking responses in individual patients with severe, treatment-resistant disease.25Archives of Medical Science. Investigative biological therapies for primary Sjögren’s syndrome These remain experimental approaches, but they reflect a growing recognition that targeting different arms of the immune system may eventually offer what current therapies cannot: meaningful disease modification rather than symptom management alone.
The Lymphoma Connection
One of the most serious long-term risks of Sjögren’s syndrome is the development of B-cell non-Hodgkin’s lymphoma, particularly a type called MALT lymphoma that tends to arise in the salivary glands. The risk is elevated well above that of the general population. Certain warning signs have been identified: persistent parotid gland enlargement, enlarged lymph nodes, an enlarged spleen, a drop in previously elevated immunoglobulin levels, or the disappearance of a previously positive rheumatoid factor. These changes may signal that a population of B-cells has shifted from reactive to malignant.26PubMed Central. MALT Lymphoma of Minor Salivary Glands in a Sjögren’s Syndrome Patient: a Case Report and Review of Literature The genetic link to TNFAIP3 variants mentioned earlier also feeds into this: MALT lymphoma development in Sjögren’s patients has been specifically associated with a polymorphism in the TNFAIP3 gene.7Modern Rheumatology Journal. Association of IRF5 (rs2004640), STAT4 (rs7574865), and TNFAIP3 (rs6920220, rs2230926) gene polymorphisms with primary Sjögren’s syndrome and its complication, MALT-lymphoma
This does not mean every Sjögren’s patient should expect lymphoma. Most will not develop it. But it does mean that ongoing monitoring, particularly of salivary gland swelling and blood markers, is a routine part of long-term care.
Who Gets Sjögren’s Syndrome
The sex disparity is striking. The vast majority of patients are women, and the typical age at diagnosis clusters around menopause. As noted earlier, declining sex hormones play a direct role, but the skew is not only hormonal. Women have stronger baseline immune responses and produce more diverse autoantibodies, a pattern that runs through many autoimmune diseases. Other female-predominant conditions like lupus and rheumatoid arthritis raise the risk of developing Sjögren’s and generate overlapping autoantibody profiles.10PubMed Central. Sex differences in Sjögren’s syndrome: a comprehensive review of immune mechanisms
Certain extraglandular features follow sex-specific patterns too. Thyroiditis, Raynaud’s phenomenon, depression, and fibromyalgia occur more frequently in women with the disease, while lymphoma occurs more frequently in men.
When the Patient Is a Child or a Man
Sjögren’s syndrome in children is uncommon and looks different. Children diagnosed with the disease report less dryness and more systemic symptoms: fever, lymph node swelling, and recurrent parotitis (swelling of the cheek glands). This atypical presentation means Sjögren’s is often low on the diagnostic radar in pediatric settings, leading to even longer delays in diagnosis than adults typically face.27PubMed Central. A systematic review of primary Sjögren’s syndrome in male and paediatric populations
Men diagnosed with primary Sjögren’s tend to be younger at diagnosis than the average adult female patient. Studies have not consistently found that male patients have different clinical or serological features compared to women, though the available data are limited by small sample sizes and varying classification criteria used across different studies.
The Microbiome as a New Frontier
Emerging research is drawing connections between the communities of microorganisms living on body surfaces and Sjögren’s disease activity. Disruptions in the oral, ocular, gut, and even genital microbiomes have been found in patients with primary Sjögren’s syndrome, and these shifts may contribute to disease onset and progression.28PubMed. Microbiome alterations in primary Sjögren’s syndrome: Regional dysbiosis and microbiome-targeted therapeutic strategies The oral microbiome is an especially intuitive target, since reduced saliva flow alters the local environment in ways that favor certain bacteria over others, potentially feeding a cycle of inflammation and tissue damage. Whether correcting these imbalances, through probiotics, diet, or other means, can meaningfully change the course of the disease is still an open question, but it represents one of the more active areas of investigation. Given how few treatments actually modify the underlying disease, any new angle is welcome.